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Abstract
Background: Currently controversy exists about the immunogenicity of seasonal trivalent influenza vaccine in certain
populations, especially the elderly. STF2.46M2e (VAX102) is a recombinant fusion protein that links four copies of the
ectodomain of influenza virus matrix protein 2 (M2e) antigen to Salmonella typhimurium flagellin, a TLR5 ligand. The
objectives of this study were to assess the feasibility of giving VAX102 and TIV in combination in an effort to achieve greater
immunogenicity and to provide cross-protection.
Methodology/Principal Findings: Eighty healthy subjects, 18-49 years old, were enrolled in May and June 2009 in a double-
blind, randomized, controlled trial at two clinical sites. Subjects were randomized to receive either TIV + VAX102 or TIV +
placebo. Both arms tolerated the vaccines. Pain at the injection site was more severe with TIV + VAX102. Two weeks after
immunization the HAI responses to the H1 and H3 antigens of TIV were higher in those that received TIV + VAX102 than in
TIV + placebo (309 vs 200 and 269 vs 185, respectively), although statistically non-significant. There was no difference in the
HAI of the B antigen. In the TIV + VAX102 arm, the geometric mean M2e antibody concentration was 0.5 mg/ml and 73%
seroconverted.
Conclusions/Significance: The combination of TIV + VAX102 has the potential to increase the immune response to the
influenza A components of TIV and to provide M2e immunity which may protect against influenza A strains not contained in
seasonal TIV.
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Introduction
Influenza causes significant morbidity and mortality with an
estimated 36,000 deaths annually in the US alone [1]. Vaccination
is the primary method of prevention. Currently licensed vaccines
require annual modifications since the vaccine is comprised of
specific strain hemagglutinin (HA) glycoprotein of the influenza
viruses anticipated to circulate in the coming year. In addition,
concerns have arisen about the immunogenicity and protection
provided by trivalent inactivated influenza vaccine (TIV) in
populations such as the elderly [2]. Ideally, a vaccine that induces
protective antibodies against viral structures of low or no
variability could provide a constant level of long lasting immunity
against influenza infection and provide sufficient immune
stimulation to provide a protective response in the populations
at highest risk for infection. One option is to use a vaccine with a
genetically stable protein such as M2e along with TIV to increase
immunogenicity and to provide greater cross-protection against
other influenza A strains not represented in the seasonal vaccine.
The M2 protein of the influenza A virus ion channel is a non-
glycosylated transmembrane protein that is expressed at high
density inthecell membraneofviralinfected cellsand atlowdensity
in the lipid membrane of the mature influenza virus [3]. This
protein undergoes little sequence variation, and antibodies to a
component of the protein have provided significant protective
activity in animal models [4]. M2e alone does not produce a
significantimmuneresponse inhumans, butdoes when presentedas
four tandem repeats genetically fused to flagellin, a TLR5 ligand
[5]. This vaccine, designated VAX102 (STF2.46M2e), was
developedbyVaxInnateCorporationasacross-protective influenza
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type 2, or fljB, (STF2; TLR5 ligand) fused to four tandem repeats of
M2e at the C-terminus of flagellin [5]. The M2e is similar to that of
the M2e of the PR8 strain used in vaccine manufacturing except for
3 amino acid residues. It is produced as a fusion protein after
purification in a prokaryotic fermentation system.
When STF2.46M2e was injected with TIV into mice there was
a 3 fold increase to the H1 component of TIV as measured by
HAI compared to TIV alone (unpublished data). The stimulation
of the innate immune system via the flagellin component of
VAX102 appeared to be the possible mechanism to enhance the
TIV response. Similarly, work using a synthetic TLR4 agonist
given with TIV and an oil emulsion has shown greater IgG2a and
IgG titers, higher HAI titers and type I cytokine responses in mice
[6]. These results suggest that VAX102 when given with TIV in
humans would enhance the immunogenicity of TIV as well as
provide better cross-protection for circulating strains through
immunity to M2e. This immunopotentiation to TIV would be
desirable for populations like the elderly who respond less well to
TIV [7]. The purpose of this study is to test the safety and
immunogenicity of this novel adjuvant-antigen in combination
with trivalent inactivated influenza vaccine in young healthy adults
18–49 years of age to determine if this combination is safe and able
to immunopotentiate the response to TIV before testing in frail,
elderly adults.
Methods
Study Design
This study, a phase I/II, double-blind, randomized, placebo-
controlled trial, was designed to assess the safety, reactogenicity
and immunogenicity of 1 mg of VAX102 investigational vaccine
administered with the previous season’s TIV, compared to placebo
+ TIV in healthy young adults at two clinical centers. The study
was approved by the Institutional Review Boards at both sites
(Vanderbilt University Medical Center and Johnson City Clin-
Trials) and was conducted May-July 2009. The trial was registered
with clinicaltrials.gov (NCT00921973). The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Participants
Forty subjects were randomized (1:1 randomization) to each
arm of the study. Subjects were considered eligible if they were age
18–49 years; able to adhere to all protocol requirements; healthy,
as determined by medical history, physical examination, vital
signs, and clinical safety laboratory examinations; and had not
received influenza vaccination (TIV) during the 2008–2009
influenza season. Female subjects needed to have a negative urine
pregnancy test within 24 hours preceding receipt of first
vaccinations and needed to fulfill one of the following criteria: at
least one year post-menopausal; surgically sterile; or willing to use
a reliable form of contraception for the duration of the study.
Subjects were considered ineligible if they had any of the
following: presence of significant acute or chronic, uncontrolled
medical or psychiatric illness, history of cancer, impaired
immunoresponsiveness (including diabetes or due to immunosup-
pressive treatment regimens), known hypersensitivity to a previous
dose of influenza vaccine, allergy to eggs or any components of the
study vaccines, receipt of influenza vaccination (TIV or LAIV)
during the 2008–2009 influenza season, had known history of
Guillain-Barre ´ Syndrome, were vaccinated with a registered
vaccine within 14 days (for inactivated vaccines) or 28 days (for
live vaccines) prior to receiving the study vaccine, had a history of
anaphylactic type reaction to injected vaccines, use of new
prescription medications started within 7 days before study entry,
receipt of any blood products, including immunoglobulin, within
the 6 months before enrollment, or had clinical signs of active
infection and/or oral temperature of $38uC (100.4uF).
Ethics
The study was approved by the Vanderbilt Institutional Review
Board and Mid*Lands IRB, Leawood, KS. Each subject signed a
written consent.
Interventions
Subjects were screened prior to enrollment to establish
eligibility. Study materials were prepared by unblinded pharma-
cists and provided to blinded clinical staff. All study participants
received Fluvirin 0.5 ml in the deltoid muscle of the non-dominant
arm. Immediately following the Fluvirin injection, study partici-
pants received VAX102 1-mg dose (0.5 ml) vaccine or the
identically appearing placebo by intramuscular injection at
approximately the same vaccination site as the Fluvirin. Subjects
remained in the clinic for 30 minutes after injection and returned
to the clinic for safety observations on Days 1, 14 and 28 for a
limited physical examination, memory aid review and laboratory
assessment. Laboratory analysis included CBC, BUN, Creatinine,
urinalysis and liver function tests.
Serum was drawn for hemagglutinin inhibition (HAI) antibodies
and antibodies to M2e and flagellin on the day of vaccination and
days 14 and 28 post-vaccination. In addition, blood was drawn to
measure C-reactive protein (CRP) on the day of vaccination and
the day following. Subjects maintained a memory aid to assess for
reactogenicity and were evaluated one day post-vaccination and
day 28 post-vaccination. Participants maintained the memory aid
following vaccination, and for 6 days thereafter, on which they
recorded solicited local and systemic reactions graded as none,
mild, moderate, or severe. Adverse reactions were assessed by
study participants using a 4 point scale (0–3) based on the
interference of daily activities where 0=no interference, 1=
minimal interference, 2= moderate decreases in functioning, and
3= severe disruption. Solicited local reactions were redness,
swelling or induration, pain and ecchymosis. Solicited systemic
reactions were fever (subjects were provided with a thermometer),
headache, joint pain, fatigue, muscle aches, shivering (chills) and
increased sweating.
Study Agents
Study Vaccine. VAX102 (STF2.46M2e[Hu]) is comprised
of 4 tandem copies of a consensus M2e sequence (46M2e) fused to
the TLR5-specific ligand Salmonella typhimurium flagellin fljB (STF)
[5].
Licensed TIV. FluvirinH (Novartis), an FDA licensed TIV for
the 2008–2009 influenza season, was used in all participants. Each
0.5-mL dose contained a total of 15 mg of influenza virus
hemagglutinin (HA) from each of the following 3 strains: A/
Brisbane/59/2007(H1N1); A/Uruguay/716/2007 (H3N2), an A/
Brisbane/10/2007-like strain; and B/Florida/4/2006.
Placebo. The placebo used in this study was the buffer used
to formulate VAX102. This buffer, designated F105, contains 10
mM Tris, 10 mM Histidine, 5% (w/v) sucrose, 75 mM NaCl, 0.1
mM EDTA, 0.5% (v/v) ethanol and 0.02% (w/v) polysorbate-80
at pH 7.2.
Laboratory Assays
HAI. Hemagglutination inhibition (HAI) antibody titers for
both influenza A and B vaccine antigens were determined in
Influenza Vaccine + VAX102
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simultaneously. HAI antibodies were determined using CDC
protocols [8] using 0.5% turkey red blood cells with representative
antigens supplied by the CDC. Serum samples were treated per
manufacturer’s instruction with receptor-destroying enzyme
(RDE) before testing. HAI assays were performed at a starting
dilution of 1:10 with subsequent serial 2-fold dilutions. Each
antigen (A/Brisbane/59/2007, A/Brisbane/10/2007, and B/
Florida/4/2006) was diluted to 8 HA units. Samples showing
high background in testing were repeated after preabsorption with
packed turkey red blood cells. Titers were determined by
identifying the last well with total lack of agglutination. Samples
where duplicate values were greater than 2-fold different were
repeated. Samples with values greater than the last dilution were
diluted further and retested. Final results were the reciprocal titer
of the lowest duplicate value.
M2e. M2e-specific IgG levels were determined by ELISA.
The M2e peptide is identical to the sequence used in the VAX102
vaccine (STF2.46M2e—SLLTEVETPIRNEWGSRSNDSSDP).
The peptide was coated on the plates at 2 mg/mL. After
overnight incubation at 2–8uC, plates were washed and blocked
(Superblock with Tween 20, Pierce, Rockford, IL, USA). Dilutions
of subject serum were prepared in a separate plate and transferred
to M2e-coated plates. After incubation and washing, plates were
developed using goat anti-human IgG conjugated with horseradish
peroxidase (HRP) (Jackson Immunochemicals, West Grove, PA,
USA), TMB substrate (Pierce One Step, Rockford, IL, USA) and
H2SO4 stop solution. Plates were read at 450 nm. Adjusted results
were calculated for each subject and bleed date. A sample with an
adjusted result of $0.174 mg/mL was considered positive. The
binding of human serum samples to M2e-coated plates was
compared to a standard curve of human polyclonal IgG. The
curve was fitted using a 4-parameter logistic equation in Softmax
Pro 5.2 (Molecular Devices, Sunnyvale, CA, USA). Pooled positive
and negative control sera were run on each plate. Results of
subject and control serum were converted from OD values to
M2e-specific IgG using the standard curve and adjusting for
dilution. Pass/fail criteria for each assay were established based on
both the standard curve performance and the adjusted results of
the positive and negative serum. The human IgG (AbD Serotec,
Raleigh, NC, USA) was bound to plates (Immulon 4 HBX,
Thermo Fisher Scientific Inc, Waltham, MA, USA) at 4-fold
dilutions starting at 3.6 mg/mL.
Flagellin (STF2). The STF2 protein was identical to the
sequence used in the VAX102 vaccine (STF2.46M2e). This
protein was coated on the plate at 1 mg/mL. After overnight
incubation at 2–8uC, plates were washed and blocked (Superblock
with Tween 20, Pierce, Rockford, IL, USA). Dilutions of subject
serum were prepared in a separate plate and transferred to STF2-
coated plates. After incubation and washing, plates were
developed with goat anti-human IgG conjugated HRP (Jackson
Immunochemicals, West Grove, PA, USA), TMB substrate (1-
Step, Pierce, Rockford, IL, USA) and H2SO4 stop solution. Plates
were read at 450 nm and adjusted results were calculated for each
subject and time point. For the STF2 ELISA, the binding of
human serum samples to STF2-coated plates was compared to a
standard curve of human polyclonal IgG. The curve was fitted as
described above. Pooled positive control sera were run on each
plate. Results of subject and control serum were converted from
OD values to STF2-specific IgG using the standard curve and
adjusted for dilution. The human IgG (AbD Serotec, Raleigh, NC,
USA) was bound to plates (Immulon 4 HBX, Thermo Fisher
Scientific, Waltham, MA, USA) at 4-fold dilutions starting at
3.6 mg/mL.
Objectives
The primary objective of the study was to assess the safety,
reactogenicity, and tolerability of VAX102 when given with
Trivalent Inactivated Influenza Vaccine (TIV) delivered in the
same arm as two separate IM injections in healthy adults 18 to 49
years. Secondary objectives included the assessment of the
immunogenicity of the VAX102 when given with TIV and the
antibody response to TIV when given with VAX102 compared to
TIV alone.
Outcomes
Safety assessment included visual assessment of the injection site
on day of administration (predose) and at 30 minutes post-dose
and on Days 1, 14 and 28; solicitation of local and systemic
reactogenicity; and local and systemic reactogenicity reporting in
the 7 days after vaccination. The immunogenicity assessment was
determined by serum IgG responses to M2e and HAI was assessed
before vaccination on Day 0 and on Days 14 and 28 after
vaccination.
Sample Size and Randomization
Selection of sample size was based on a calculation using 80%
power, a type I probability of 0.05, and a 40% higher rate of
seroconversion of the TIV + VAX102 arm compared to the TIV +
placebo arm. The study was not powered to detect a difference of
less than 40%. The randomization was done by block random-
ization, block size fixed at 4, and was stratified by clinical site.
Eligible subjects were assigned to an arm according to a
randomization code provided by an independent statistician.
The independent statistician provided the randomization infor-
mation to the investigational pharmacist or designee. Investiga-
tional vaccine was prepared by an unblinded investigational
pharmacist who was not involved in vaccine administration or
subsequent clinical assessments. Sponsor personnel involved in
generation and recording of immunogenicity assays were blinded
until all assays and repeats were completed and final data sets were
provided to data management personnel and locked in the
database.
Statistical Analyses
The study hypothesis was that VAX102 vaccine when
administered with TIV, intramuscularly, would be generally
well-tolerated and would elicit M2e and HAI antibodies greater
than, those elicited by the placebo with TIV delivered intramus-
cularly. Immunogenicity parameters included the geometric mean
of pre- and post-vaccination anti-M2e and HAI serum antibody
concentrations and the proportion of subjects with an M2e and
HAI specific antibody after vaccination. In general, categorical
variables were summarized by study arm as frequencies and
percentages in each category. Continuous variables were summa-
rized by study arm as numbers of subjects, means, standard
deviations, medians, and minimum/maximum values. Wilcoxon
rank sum test was used to calculate p-values for the geometric
means. Statistical analyses were performed at the two-sided
significance level of a=0.05 unless otherwise stated. No
adjustments were made for multiple statistical testing. All
programs for data output and analyses were written in SASH
version 9.1 (SAS Institute, Cary, NC) and STATA
TM version 9
(StataCorp, College Station, TX).
All analyses were based upon a per-protocol cohort with
additional analysis performed for the intent-to-treat (ITT) cohort.
The per-protocol cohort is defined as all volunteers who completed
immunization. The primary immunogenicity population consisted
Influenza Vaccine + VAX102
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post-baseline anti-M2e serum antibody or HAI titers. Safety and
tolerability analyses included all subjects and included descriptive
statistics. Frequency of vaccination site abnormalities; incidence of
local and systemic AEs and their relationship to the study drug;
and changes in clinical laboratory results, vital signs, and physical
examination findings were the primary safety measures.
Anti-M2e or HAI serum antibody titers were listed and
summarized for each time point that data were available. The
mean change from baseline to Day 14 and 28 (62) in the log-
transformed anti-M2e or HAI serum antibody reciprocal titers
were compared to zero within treatment arms using t-tests and
the data was assumed to be log-normally distributed. The 95%
CI for the geometric mean was calculated by deriving the 95%
CI around the mean on the log scale and then taking the antilog
of the confidence interval on the log scale. HAI results were also
stratified by gender. Seroprotection was defined as a post-
vaccination HAI titer of $1:40 and seroconversion was defined
either as an initial titer ,10 and a post-vaccination titer $40 or
as an initial titer $10 and a four-fold rise or greater increase in
titer compared to baseline. Seroconversion for M2e was defined
as having a 4-fold or greater increase in anti-M2e antibody
concentration compared to baseline and having a post-baseline
value $0.174 mg/mL of IgG.
Results
A total of 80 subjects were enrolled (40 at each site) during May
and June 2009. All subjects completed the protocol through day
14. 39 subjects in the VAX102 + TIV arm and 36 in the placebo +
TIV arm completed through day 28. Subjects were similar except
for a higher proportion of males in the TIV + placebo arm
(Table 1).
Immunogenicity
The HAI pre-vaccination geometric mean titers (GMT) for all
three TIV antigens were similar between both arms (table 2). The
participants in the VAX102 + TIV arm had approximately a 1.5
fold greater response to those in the placebo + TIV arm for both
H1N1 and H3N2 on day 14 but this was not statistically significant
(table 2, figure 1). These results were consistent at the two clinical
sites. Table 3 shows the HAI responses stratified by gender for
each study arm. The greatest fold change associated with the
VAX102 vaccine was seen in the men. Table 4 also shows the
seroprotection and seroresponse at Days 14 and 28 post-
vaccination with similar results seen in both arms.
In the arm that received the combination of VAX102 + TIV 29
(73%)of 40 subjectsseroconverted toM2e aftera single dose (Table 5).
The M2e antibody concentration was very low at baseline (0.04) and
rose to 0.52 post-vaccination, an approximately 10-fold increase. The
flagellin antibody titers increased from 0.74 to 27, a more than a 30-
fold increase. The CRP was measured pre-vaccination on day 0 and
on the following day. There was a minimal increase in CRP in the
arm that received TIV + placebo while there was a mean 6-fold
increase among subjects who received TIV + VAX102 (Table 5).
Reactogenicity
In general the vaccinations were well tolerated among the 80
subjects. According to patient self-report, none of the subjects in
either arm had fever. In addition, temperature was measured in
the clinic on days 1, 14 and 28 and those were within normal
range. Most local and systemic symptoms were mild or moderate
in severity (Table 6). Nearly all subjects had some degree of pain at
the site of injection. Most were mild in TIV + placebo arm and
most were moderate in the TIV + VAX102 arm. Three subjects
Table 1. Baseline characteristics of the study subjects
according to study arm comparing standard trivalent
influenza vaccine and placebo to TIV and VAX102
(STF2.46M2e).
Characteristic
TIV + placebo
N=40 (%)
TIV + VAX102
N=40 (%)
Gender (% male) 20 (50) 12 (30)
Race
White
Black
Other
Ethnicity (% Hispanic)
30 (75)
7 (17.5)
3 (7.5)
0 (0)
28 (70)
11 (27.5)
1 (2.5)
3 (7.5)
Age
Mean (years)
Median (range, years)
29.8
26.5 (18–49)
28.2
25.0 (18–48)
Received influenza vaccine
in last 5 years
12 (30) 13 (32.5)
doi:10.1371/journal.pone.0014442.t001
Table 2. HAI Geometric Mean Immunologic Responses among subjects who received one dose of TIV co-administered with
placebo or VAX102 as a separate injection at the same anatomical location.
HAI TIV + placebo TIV + VAX102
N=40 N=40
Vaccine Strain Days Post-vaccination GMT
{ 95% CI GMT
{ 95% CI Ratio
H1N1 0
14
28
12
200
165
8, 19
127, 314
97, 281
16
309
240
10, 23
188, 506
147, 392
1.54
1.46
H3N2 0
14
28
11
184
151
8, 16
96, 353
76, 297
9
269
184
7, 12
166, 435
114, 297
1.46
1.22
B0
14
28
46
590
458
26, 82
360, 966
252, 832
60
541
514
39,94
371, 789
349, 756
0.92
1.12
GMT = Geometric Mean Titer.
doi:10.1371/journal.pone.0014442.t002
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Redness and swelling at the site of injection were not reported in
the TIV + placebo arm compared to about 20% of the subjects
reported mild to moderate redness and swelling with TIV +
VAX102. Systemic symptoms occurred infrequently in both arms.
Muscle aches were the most common occurring in 7.5% in the
placebo arm and 37.5% in the VAX102 arm. In the placebo arm,
5 subjects had an adverse event, all mild or moderate, and all were
considered unrelated to vaccine. In the VAX102 arm, 8 subjects
had an adverse event, all mild to moderate. Only one of these,
injection site erythema, was considered to be due to the injection.
Discussion
This study was a phase I/II to evaluate the safety and
immunogenicity of an M2e protein influenza vaccine when given
with seasonal TIV in young healthy adults. Although limited by
sample size, this study did show a statistically non-significant
increase of approximately 1.5 fold in the GMT of the HAI
response to both H1N1 and H3N2. In contrast there was little
difference in the influenza B component. The immune response to
influenza B was the highest compared to the other antigens and it
is unlikely that they could be further enhanced with the addition
VAX02. Further, in contrast to the 24 residue M2 ectodomain of
influenza A, the M2 ectodomain of influenza B has only 7 residues.
[9] Thus it is unlikely that A/M2e could enhance the immune
response of influenza B. The seroprotection and seroconversion
rates were similar for both arms but this is likely due to the high
baseline titers in both arms (likely due to a history of prior
vaccination and infection) and due to the historically good
responses seen to vaccination in this age group compared to
adults $65 years of age. [7] In a recent study by Falsey et al. [10] a
high dose TIV with a 4-fold increase in HA content was only able
to induce a 1.7 fold increase in H1N1 or H3N2 titer in older
adults. The current study, performed in young adults, produced a
similar rise of 1.5 fold. Interestingly the greatest fold change was
seen in men. Two factors appeared to account for this difference.
One was that females had a 2–3 fold higher response than males.
It appears that if the response is poor than M2e can enhance the
response, but if the response is strong the addition of M2e does not
add much. Gender differences have been previously seen with
pertussis vaccination where women had a slightly lower antibody
response than men [11].
Table 3. CRP and HAI Geometric Mean Immunologic Responses among subjects who received one dose of TIV co-administered
with placebo or VAX102 as a separate injection at the same anatomical location, stratified by gender for each study arm.
TIV + Plac TIV + M2e TIV + Plac TIV + M2e
SEX Males Males Females Females
Subject n=20 n=12 Ratio n=20 n=28 Ratio
CRP D0 0.9 0.6 0.7 1.1 2.0 1.8
CRP D1 0.9 6.4 7.3 1.3 10.4 7.9
CRP Fold 1.0 10.4 10.4 1.2 5.1 4.4
H1N1 d0 12 15 1.2 13 16 1.3
H1N1 d14 144 359 2.5 279 290 1.0
H1N1 d28 104 300 2.9 240 221 0.9
H1 fold d14 12 24 2.0 22 18 0.8
H1 fold d28 10 21 2.2 19 13 0.7
H3N2 d0 8 11 1.4 17 9 0.5
H3N2 d14 113 214 1.9 302 297 1.0
H3N2 d28 80 150 1.9 251 200 0.8
H3 fold d14 14 20 1.4 18 33 1.8
H3 fold d28 10 17 1.7 15 22 1.5
B-FL d0 49 53 1.1 44 64 1.4
B-FL d14 590 570 1.0 591 530 0.9
B-FL d28 553 497 0.9 394 521 1.3
B fold d14 12 11 0.9 13 8 0.6
B fold d28 13 9 0.7 9 8 0.9
doi:10.1371/journal.pone.0014442.t003
Figure 1. Comparison of Geometric Mean HAI Titers among
subjects who received TIV +placebo or TIV plus VAX102.
doi:10.1371/journal.pone.0014442.g001
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not noted in the placebo arm. Even though the M2e component of
VAX102 has a difference of 3 amino acids compared to the PR8
virus which is used for vaccine manufacturing, a prior study has
shownthatmiceareabletogenerateimmuneserumthatwillreactto
M2e from multiple different origins. [12] Antibodies to M2e are
protective in animal models, [4,5] but there are no clinical studies
testing the efficacy of M2e or any estimates of immunologic
correlates of protection. Future studies will need to determine the
level of additional protection provided by anti-M2e antibody and
increased HAI antibody titers. CRP responses were elevated in the
arm that was immunized with TIV + VAX102 but not in the arm
that received TIV + placebo. CRP rises when interleukin-6 is
elevated which is most likely due to the stimulation of the TLR5
receptor by flagellin. [13] TIV alone does not induce this type of
response. The stimulation of theinnate immune systembyflagellin is
what induces the M2e antibody response and appears also to
enhance the response to the hemagglutinin component of TIV. The
M2e component of VAX102 is derived from the consensus sequence
ofhumaninfluenzaAstrains.ItisinterestingthatVAX102increased
the immuneresponseto the influenzaA componentsof TIV,namely
the H1 and H3 components but did not improve the B component.
The response to the B strain was the highest of all three antigens and
it is possible that it was maximally stimulated.
Due to the concerns about the effectiveness of the current TIV
in older adults, Poland et al. [2] summarized the available and
Table 4. Seroprotection (SP) and seroresponse (SR) rates
among subjects who received one dose of TIV
co-administered with placebo or VAX102 as a separate
injection at the same anatomical location.
Vaccine
Strain
Days
post-
vaccination TIV + placebo TIV + VAX102
%S P %S C %S P %S C
0 22.5 35
H1N1 14 92.5 75 92.5 82.5
28 88.9 77.8 92.3 76.9
0 20 12.5
H3N2 14 82.5 80 90 90
28 77.8 75 87.2 87.2
06 5 7 5
B 14 97.5 82.5 95 75
28 94.4 69.4 97.4 74.4
Seroprotection is post-vaccination HAI titer of $1:40.
Seroresponse is either an initial HAI ,10 and a post vaccination titer $40 or an
initial titer $10 and a 4-fold or greater increase in titer compared to baseline.
doi:10.1371/journal.pone.0014442.t004
Table 5. Geometric Mean Concentration (GMC) Antibody
Response to M2e and flagellin and CRP response after one
dose of VAX102.
TIV + Placebo TIV + M2e
Days post-vaccination N=40* N=40** p-value
M2e antibody response
Day 0 0.03 0.04
Day 14 0.04 0.52 0.007
Day 28 0.04 0.46 0.013
Geo. Mean fold rise day 14 1.06 11.9
Geo. Mean fold rise day 28 1.1 9.99
Seroconversion rate{ 0 29 (73%)
Flagellin antibody
response
Day 0 0.52 0.74
Day 14 0.51 26.78 0.0002
Day 28 0.55 21.97 0.0023
Geo. Mean fold rise day 14 0.98 36.25
Geo. Mean fold rise day 28 1.04 29.74
CRP value
Day 0 1 1.41
Day 1 1.08 8.97 ,0.0001
Geo. Mean fold rise 1.08 6.35
*For Day 28 values N=36.
**For Day 28 values N=39.
{Seroconversion to M2e was defined as a serum IgG anti-M2e antibody value
$0.174 mg/ml and a four-fold rise in titer.
doi:10.1371/journal.pone.0014442.t005
Table 6. Solicited local and systemic reactogenicity within 7
days of either trivalent influenza vaccine (TIV) and placebo or
TIV and VAX102 given in the same arm.
Symptom Severity
TIV + placebo
N=40 (%)
TIV + VAX102
N=40 (%)
Fever Mild
Moderate
Severe
0( 0 )
0( 0 )
0( 0 )
0 (0)
0 (0)
0 (0)
Redness Mild
Moderate
Severe
0( 0 )
0( 0 )
0( 0 )
1 (2.5)
8 (20)
0 (0)
Swelling Mild
Moderate
Severe
0( 0 )
0( 0 )
0( 0 )
4 (10)
3 (7.5)
0 (0)
Bruising Mild
Moderate
Severe
0( 0 )
0( 0 )
0( 0 )
1 (2.5)
0 (0)
0 (0)
Injection Site Pain Mild
Moderate
Severe
11 (27.5)
3 (7.5)
0( 0 )
8 (20)
24 (60)
3 (7.5)
Headache Mild
Moderate
Severe
5 (12.5)
2( 5 )
0( 0 )
10 (25)
3 (7.5)
1 (2.5)
Fatigue Mild
Moderate
Severe
3 (7.5)
2 (5.0)
0( 0 )
7 (17.5)
2 (5.0)
0 (0)
Joint Pain Mild
Moderate
Severe
0( 0 )
1 (2.5)
0( 0 )
1 (2.5)
0 (0)
0 (0)
Muscle Ache Mild
Moderate
Severe
2 (5.0)
1 (2.5)
0( 0 )
9 (22.5)
5 (12.5)
1 (2.5)
Shivering/Chills Mild
Moderate
Severe
0( 0 )
0( 0 )
0( 0 )
1 (2.5)
0 (0)
0 (0)
Increased Sweating Mild
Moderate
Severe
1 (2.5)
1 (2.5)
0( 0 )
0 (0)
1 (2.5)
0 (0)
doi:10.1371/journal.pone.0014442.t006
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strategies to improve the effectiveness of the current TIV. The
combination of VAX102 + TIV would be another possibility for
an improved vaccine formulation. The increased immunogenicity
and addition of greater strain cross-protection would theoretically
increase the number of senior citizens protected from influenza.
This preliminary work has shown the VAX102 when used in
combination with TIV to have the potential to improve the
immunologic response to TIV alone. This combination may have
promise in high-risk populations such as the elderly.
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